Study to Evaluate Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma

NCT ID: NCT05274815

Last Updated: 2025-12-11

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 305 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-05-17
• Study Completion Date: 2024-09-09

Brief Summary

This is a study designed to evaluate efficacy and safety of Tezepelumab in reducing oral corticosteroid use in adult patients with severe asthma who are receiving oral corticosteroids with or without additional asthma controller medications.

Detailed Description

This is a multicentre, single-arm, phase 3b study designed to evaluate efficacy and safety of reducing daily oral corticosteroid use after initiation of 210 mg dose of Tezepelumab administered subcutaneously in patients with severe asthma receiving high-dose inhaled corticosteroid plus long-acting β2 agonist and oral corticosteroids with or without additional asthma controller medications.

Conditions

Asthma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Tezepelumab

Tezepelumab subcutaneous injection

Group Type: EXPERIMENTAL

Tezepelumab

Intervention Type: BIOLOGICAL

Tezepelumab subcutaneous injection

Interventions

Tezepelumab

Tezepelumab subcutaneous injection

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Age 18-80 years.
• Documented physician diagnosed asthma requiring continuous treatment with high-dose ICS plus a LABA for at least 6 months prior to Visit 1. The ICS and LABA can be contained within a combination product or given by separate inhalers.
• Documented long-term OCS therapy for asthma, equivalent to a daily dose of at least 5 mg and up to 40 mg of prednisone/prednisolone for at least 3 continuous months directly preceding Visit 1.
• Participant should be on a stable maintenance OCS dose for at least 4 weeks prior to Visit 1.
• Documented history of at least 1 asthma exacerbation event within 12 months prior to Visit 1.

Exclusion Criteria

• Pulmonary disease or systemic diseases, other than asthma associated with elevated peripheral EOS counts.
• Any disorder or major physical impairment that is not stable and could affect the safety of the participant throughout the study, influence the findings of the study or the interpretation, or impede the participant's ability to complete the entire duration of study.
• History of cancer.
• History of a clinically significant infection requiring treatment with antibiotics, antiviral or additional corticosteroid medications finalised < 2 weeks before Visit 1.
• A helminth parasitic infection diagnosed within 6 months prior to Visit 1 that has not been treated with, or has failed to respond to, standard of care therapy.
• Current smokers or participants with smoking history ≥ 10 pack-years and participants using vaping products, including electronic cigarettes.
• History of chronic alcohol or drug abuse within 12 months prior to Visit 1.
• Tuberculosis requiring treatment within the 12 months prior to Visit 1.
• History of known immunodeficiency disorder including a positive HIV test at Visit 1.
• Major surgery within 8 weeks prior to Visit 1 or planned surgical procedures requiring general anaesthesia or inpatient status for > 1 day during the conduct of the study.
• Coexistent inflammatory conditions for which long-term OCS doses are part of their maintenance treatment.
• Receipt of any marketed or investigational biologic agent within 4 months or 5 half-lives (whichever is longer) prior to Visit 1 or receipt of any investigational nonbiologic agent within 30 days or 5 half-lives (whichever is longest) prior to Visit 1. Participants enrolled in current or previous tezepelumab studies will not be included.
• Concurrent enrolment in another clinical study involving an IP.
• Treatment with systemic immunosuppressive/immunomodulating drugs, except for OCS used in the treatment of asthma/asthma exacerbations, within the last 12 weeks or 5 half-lives (whichever is longer) prior to Visit 1.
• History of anaphylaxis or documented immune complex disease (Type III hypersensitivity reactions) following any biologic therapy.
• Positive hepatitis B surface antigen, or hepatitis C virus antibody serology at screening, or a positive medical history for hepatitis B or C.
• Pregnant, breastfeeding, or lactating women.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

AstraZeneca

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Research Site

Newport Beach, California, United States

Research Site

Newark, Delaware, United States

Research Site

Loxahatchee Groves, Florida, United States

Research Site

Ann Arbor, Michigan, United States

Research Site

Toms River, New Jersey, United States

Research Site

The Bronx, New York, United States

Research Site

DuBois, Pennsylvania, United States

Research Site

Buenos Aires, , Argentina

Research Site

CABA, , Argentina

Research Site

CABA, , Argentina

Research Site

Mendoza, , Argentina

Research Site

Monte Grande, , Argentina

Research Site

Pilar, , Argentina

Research Site

Quilmes, , Argentina

Research Site

Ranelagh, , Argentina

Research Site

Rosario, , Argentina

Research Site

San Fernando, , Argentina

Research Site

San Juan Bautista, , Argentina

Research Site

San Miguel de Tucumán, , Argentina

Research Site

Brussels (Woluwé-St-Lambert), , Belgium

Research Site

Erpent, , Belgium

Research Site

Ghent, , Belgium

Research Site

Liège, , Belgium

Research Site

Haskovo, , Bulgaria

Research Site

Razgrad, , Bulgaria

Research Site

Sofia, , Bulgaria

Research Site

Sofia, , Bulgaria

Research Site

Sofia, , Bulgaria

Research Site

Velika Tarnovo, , Bulgaria

Research Site

Antony, , France

Research Site

Bordeaux, , France

Research Site

Brest, , France

Research Site

Lyon, , France

Research Site

Marseille, , France

Research Site

Montpellier, , France

Research Site

Nantes, , France

Research Site

Nice, , France

Research Site

Berlin, , Germany

Research Site

Darmstadt, , Germany

Research Site

Fürstenwalde, , Germany

Research Site

Mainz, , Germany

Research Site

Reinfeld (Holstein), , Germany

Research Site

Daugavpils, , Latvia

Research Site

Daugavpils, , Latvia

Research Site

Jūrmala, , Latvia

Research Site

Riga, , Latvia

Research Site

Riga, , Latvia

Research Site

Riga, , Latvia

Research Site

Valmiera, , Latvia

Research Site

Chihuahua City, , Mexico

Research Site

Chihuahua City, , Mexico

Research Site

Guadalajara, , Mexico

Research Site

Monterrey, , Mexico

Research Site

Bychawa, , Poland

Research Site

Chmielnik, , Poland

Research Site

Gdansk, , Poland

Research Site

Krakow, , Poland

Research Site

Lodz, , Poland

Research Site

Ostrowiec Świętokrzyski, , Poland

Research Site

Sosnowiec, , Poland

Research Site

Wroclaw, , Poland

Research Site

Wroclaw, , Poland

Research Site

Wroclaw, , Poland

Research Site

Badalona, , Spain

Research Site

Barcelona, , Spain

Research Site

Madrid, , Spain

Research Site

Oviedo, , Spain

Research Site

Santa Cruz de Tenerife, , Spain

Research Site

Santander, , Spain

Research Site

Seville, , Spain

Research Site

Belfast, , United Kingdom

Research Site

Bradford, , United Kingdom

Research Site

LE3 9QP, , United Kingdom

Research Site

London, , United Kingdom

Research Site

London, , United Kingdom

Research Site

Nottingham, , United Kingdom

Research Site

Portsmouth, , United Kingdom

Countries

United States; Argentina; Belgium; Bulgaria; France; Germany; Latvia; Mexico; Poland; Spain; United Kingdom

References

Jackson DJ, Lugogo NL, Gurnell M, Heaney LG, Korn S, Brusselle G, Chanez P, Del Olmo R, Llanos JP, Keeling N, Salapa K, Cook B, Parulekar AD, Kostikas K, Fogel R, Martin N, Chandarana SN. Oral corticosteroid reduction and discontinuation in adults with corticosteroid-dependent, severe, uncontrolled asthma treated with tezepelumab (WAYFINDER): a multicentre, single-arm, phase 3b trial. Lancet Respir Med. 2025 Nov 26:S2213-2600(25)00359-5. doi: 10.1016/S2213-2600(25)00359-5. Online ahead of print.

Reference Type: DERIVED

PMID: 41317738 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5180C00037&amp;attachmentIdentifier=34d82b3c-095c-46d3-988d-684d6a36c498&amp;fileName=D5180C00037_CSP_Redacted.pdf&amp;versionIdentifier=

Redacted CSP

https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5180C00037&amp;attachmentIdentifier=c0811001-71fd-4900-8ccb-2c061b7cf697&amp;fileName=D5180C00037_CSR_Synopsis.pdf&amp;versionIdentifier=

Redacted CSR Synopsis

https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5180C00037&amp;attachmentIdentifier=0ed21781-6d75-4e43-b87d-e42dfdc3186a&amp;fileName=D5180C00037_SAP_Redacted.pdf&amp;versionIdentifier=

Redacted SAP

Other Identifiers

2021-005457-85

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

D5180C00037

Identifier Type: -

Identifier Source: org_study_id